225 related articles for article (PubMed ID: 18088160)
21. Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain.
Cámara R; Gozalbo I; Jurado M; Sanz J; Aragón B; Grau S
Adv Ther; 2017 Sep; 34(9):2104-2119. PubMed ID: 28808915
[TBL] [Abstract][Full Text] [Related]
22. Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology.
Huijgens PC; Simoons-Smit AM; van Loenen AC; Prooy E; van Tinteren H; Ossenkoppele GJ; Jonkhoff AR
J Clin Pathol; 1999 May; 52(5):376-80. PubMed ID: 10560360
[TBL] [Abstract][Full Text] [Related]
23. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D
N Engl J Med; 2007 Jan; 356(4):348-59. PubMed ID: 17251531
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of primary antifungal prophylaxis with posaconazole versus itraconazole in allogeneic hematopoietic stem cell transplantation.
Sánchez-Ortega I; Patiño B; Muñoz C; Arnan M; Peralta T; Clopés A; de Sevilla AF; Duarte RF
J Med Econ; 2013; 16(6):736-43. PubMed ID: 23541251
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease.
O'Sullivan AK; Weinstein MC; Pandya A; Thompson D; Langston AA; Perfect JR; Papadopoulos G
Am J Health Syst Pharm; 2012 Jan; 69(2):149-56. PubMed ID: 22215361
[TBL] [Abstract][Full Text] [Related]
26. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients.
Glasmacher A; Prentice A; Gorschlüter M; Engelhart S; Hahn C; Djulbegovic B; Schmidt-Wolf IG
J Clin Oncol; 2003 Dec; 21(24):4615-26. PubMed ID: 14673051
[TBL] [Abstract][Full Text] [Related]
27. Cost benefit and cost effectiveness of antifungal prophylaxis in immunocompromised patients treated for haematological malignancies: reviewing the available evidence.
Pechlivanoglou P; De Vries R; Daenen SM; Postma MJ
Pharmacoeconomics; 2011 Sep; 29(9):737-51. PubMed ID: 21657801
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
Sohn HS; Lee TJ; Kim J; Kim D
Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
[TBL] [Abstract][Full Text] [Related]
29. [Prophylaxis of fungal infection in patients with hematologic neoplasms and severe neutropenia after high-dose chemotherapy].
Minenko SV; Zhukov NV; Chimishkian KL; Sokolova EN; Ptushkin VV
Antibiot Khimioter; 2004; 49(8-9):52-6. PubMed ID: 15727147
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation.
Schonfeld W; Wang Cheng J; Tong KB; Seifeldin R
Clin Ther; 2008 May; 30(5):964-73. PubMed ID: 18555943
[TBL] [Abstract][Full Text] [Related]
31. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole.
Glasmacher A; Hahn C; Leutner C; Molitor E; Wardelmann E; Losem C; Sauerbruch T; Marklein G; Schmidt-Wolf IG
Mycoses; 1999; 42(7-8):443-51. PubMed ID: 10546485
[TBL] [Abstract][Full Text] [Related]
32. The cost-utility analysis of antifungal prophylaxis for invasive fungal infections in acute myeloid leukaemia patients receiving chemotherapy: a study from a middle-income country.
Pungprasert T; Dhirachaikulpanich D; Phutthasakda W; Tantai N; Maneeon S; Nganthavee V; Atipas K; Tanpong S; Krithin S; Tanglitanon S; Jutidamrongphan W; Chayakulkeeree M; Srinonprasert V; Phikulsod P
J Hosp Infect; 2024 Mar; 145():118-128. PubMed ID: 38219835
[TBL] [Abstract][Full Text] [Related]
33. Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.
Solano C; Slavin M; Shaul AJ; Marks DI; Cordonnier C; Cornely OA; Pagliuca A; Cragin L; Jarque I; Garcia-Vidal C; Sorensen S; Vanness DJ; Charbonneau C; Barrueta JA; Peral C; De Salas-Cansado M; Bow EJ
Mycoses; 2017 Feb; 60(2):79-88. PubMed ID: 27562016
[TBL] [Abstract][Full Text] [Related]
34. In meta-analysis itraconazole is superior to fluconazole for prophylaxis of systemic fungal infection in the treatment of haematological malignancy.
Prentice AG; Glasmacher A; Djulbegovic B
Br J Haematol; 2006 Mar; 132(5):656-8; author reply 658-9. PubMed ID: 16445845
[No Abstract] [Full Text] [Related]
35. Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia.
Döring M; Eikemeier M; Cabanillas Stanchi KM; Hartmann U; Ebinger M; Schwarze CP; Schulz A; Handgretinger R; Müller I
Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1189-200. PubMed ID: 25680318
[TBL] [Abstract][Full Text] [Related]
36. Medical cost analysis for antifungal prophylaxis in neutropenic patients with hematological malignancies: a systematic simulation analysis.
Imataki O; Kubota Y; Ohnishi H; Kitanaka A; Ishida T; Tanaka T
Support Care Cancer; 2011 Oct; 19(10):1657-65. PubMed ID: 20830490
[TBL] [Abstract][Full Text] [Related]
37. Mixed treatment comparison of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for haematological malignancies: a systematic review.
Pechlivanoglou P; Le HH; Daenen S; Snowden JA; Postma MJ
J Antimicrob Chemother; 2014 Jan; 69(1):1-11. PubMed ID: 23975736
[TBL] [Abstract][Full Text] [Related]
38. [Economic evaluation of the treatment of systemic fungal infections in immunocompromised patients: the role of itraconazole].
Colombo GL; Morlotti L; Serra G
Recenti Prog Med; 2005 Sep; 96(9):416-23. PubMed ID: 16229321
[TBL] [Abstract][Full Text] [Related]
39. Fluconazole versus oral polyenes in the prophylaxis of immunocompromised patients: a cost-minimization analysis.
Wakerly L; Craig AM; Malek M; Hoffmeyer U; Lloyd A; Valette F; Phillips R; Zabihollah M
J Hosp Infect; 1996 May; 33(1):35-48. PubMed ID: 8738200
[TBL] [Abstract][Full Text] [Related]
40. Antifungal prophylaxis with itraconazole oral solution in neutropenic patients.
Kibbler CC
Mycoses; 1999; 42 Suppl 2():121-4. PubMed ID: 10865918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]